Filip Markovic

9PUBLICATIONS
13CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)ChemotherapyMolecular targetsPredictive and prognostic markersRadiology and organ imaging
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|May 26, 2026
Clinical Outcomes and Immune-Related Adverse Events in Metastatic Non-Squamous NSCLC Treated with First-Line Pembrolizumab-Chemotherapy: A Real-World Study from Serbia.

|Apr 14, 2026
Real-World Comparison of PD-1 and PD-L1 Inhibitor Monotherapy in Metastatic Non-Small Cell Lung Cancer with High PD-L1 Expression.

Filip Marković, Zlatan Bojić, Mihailo Stjepanović

|Feb 26, 2026
Immune-Related Thyroid Dysfunction in PD-L1 High Non-Oncogene-Addicted NSCLC Treated with First-Line Pembrolizumab: Incidence, Timing, and Predictive Impact.

Filip Marković, Mihailo Stjepanović, Milica Kontić

|Jan 28, 2026
Comparison of the Efficacy of Pirfenidone and Nintedanib in the Treatment of Patients with Idiopathic Pulmonary Fibrosis-A Single-Center Experience.

Nikola Trboljevac, Sanja Dimic-Janjic, Milica Kontic

|Aug 28, 2025
Beyond the Tissue: Unlocking NSCLC Treatment Potential Through Liquid Biopsy.

Milica Kontic, Mihailo Stjepanovic, Filip Markovic

|Jul 23, 2025
Hypermethylation of SOX1 and HOXA9 Genes Is Associated with Clinicopathologic Characteristics of Non-Small Cell Lung Cancer Patients.

Milica Kontić, Mihailo Stjepanović, Filip Marković

Pageof 2

Frequent Collaborators

8 joint publications

Mihailo Stjepanovic

5 joint publications

Milica Kontić

2 joint publications

Sanja Dimic-Janjic

1 joint publications

Ivan Milivojevic